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I. Experimental Procedures 
 
General Unless otherwise noted, all chemicals and reagents were obtained from commercial 
suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further purification. Silica gel 
chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. Synthetic reactions 
were monitored using thin layer chromatography (Merck 60 gel plates) using a UV-lamp for 
visualization. 1H and 13C NMR spectra were recorded on a Varian Inova 300 MHz or 500 MHz, 
or Bruker Prodigy 400 MHz instrument, in CDCl3 and are internally referenced to the residual 
solvent peak. Data for 1H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublets, dt 
= doublet of triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
High-resolution mass spectra were obtained at the California Institute of Technology Mass 
Spectrometry Facility.  
 
Chromatography. Analytical reversed-phase high-performance liquid chromatography (HPLC) 
was carried out using an Agilent 1200 series instrument with water and acetonitrile as the mobile 
phases using either a Kromasil 100-5-C18 column (4.6 x 50 mm, 5 µM) or a Poroshell 120 C18 
column (4.6 x 50 mm, 5 µM). For quantitative HPLC analyses of alkylation or cyclopropanation 
reactions, calibration curves using either ethyl benzoate or 1,3,5-trimethoxybenzene as internal 
standards were generated (Supplementary Figures 9 to 14). The identity of enzymatic reaction 
products was confirmed by HPLC or GC-MS co-injections of enzymatic reaction mixtures with 
chemically synthesized authentic products, and/or by NMR analysis of products isolated from 
reactions performed on preparative scale. Enantiomeric products were separated by normal-
phase chiral HPLC on an Agilent 1200 series instrument with isopropanol and hexane as the 
mobile phase, using Chiralpak IA or IC columns (4.6 x 250 mm, 5 μm). Analytical gas 
chromatography coupled to mass spectrometry (GC-MS) was carried out on a Shimadzu GCMS-
QP2010SE instrument equipped with a J&W HP-5ms column. For quantitative GC-MS analyses 
of cyclopropanation reaction products, calibration curves using 1,3,5-trimethoxybenzene as 
internal standards were generated (Supplementary Figure 15). 
 
Cloning and site-saturation mutagenesis. pET22b(+) (Novagen) with the pelB leader sequence 
removed was used as a cloning and expression vector for all constructs described in this study. 
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Site-saturation mutagenesis libraries were generated using the 22c-trick method;1 random 
mutagenesis libraries were cloned using Taq polymerase (NEB) and various concentrations of 
MnCl2 (typically, 100-400 µM) to steer polymerase error rate. Primers were obtained from IDT 
(primer sequences are available upon request). PCR was performed using Phusion polymerase 
(NEB) and the resulting PCR products were digested with DpnI (NEB), gel purified (Zymo 
Research), repaired using the method of Gibson,2 and used to directly transform E. coli strain 
BL21(DE3) (Lucigen) by electroporation. Following electroporation, cells were recovered for 
45 min at 37º C in Luria-Bertani (LB) medium, aliquots were plated on LB agar plates 
supplemented with 100 µg/mL ampicillin (LB-Amp plates), and plates were incubated at 37º C 
overnight. 
 
High-throughput spectrophotometric library screening in 96-well plate format. Single 
colonies of E. coli BL21(DE3) cells transformed with site-saturation or random mutagenesis 
libraries (or cells transformed with plasmid encoding the corresponding parent variant) were 
picked with sterile toothpicks and cultured in 96-deep-well plates in LB-Amp medium 
(300 µL/well) at 37 ºC, 250 rpm, overnight. In a fresh 96-deep-well plate, Hyperbroth medium 
(AthenaES, 950 µL/well, supplemented with 100 µg/mL ampicillin (HB-Amp)) was inoculated 
with the pre-cultures (50 µL/well) and incubated at 37 ºC, 250 rpm, for 2.5 h. The plates were 
cooled on ice for 20 minutes and then induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 1.0 mM 5-aminolevulinic acid (ALA) (final concentrations). 
Expression was conducted at 24 ºC, 200 rpm for 16-20 h. The cells were pelleted (3,000 × g, 
5 min), the supernatant was discarded, and the 96-well plates were transferred to an anaerobic 
chamber (generations 1a to 2, see Supplementary Table 2 below; as well as all evolutions for 
substrate scope shown in Figure 4 in the main text) or reactions were set up at the bench under 
standard atmosphere (generations 3 to 6). Cell pellets were resuspended in reaction buffer (M9-N 
with 20 mM D-glucose, 370 µL/well. M9-N minimal medium is 47.7 mM Na2HPO4, 22.0 mM 
KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2, adjusted to pH 7.4 at room 
temperature), and stocks of olefin (15 µL/well, in EtOH or DMSO) and diazo reagent 
(15 µL/well, in EtOH) were added. Substrate concentration typically varied, depending on the 
reaction tested, between 10 and 30 mM for both heterocycles and diazo reagent. Following 
substrate addition the plates were sealed with aluminum foil and shaken at 500 rpm, room 
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temperature, overnight. After overnight incubation, the seal was removed and reactions were 
worked up for either HPLC or GC-MS analysis. For HPLC analysis, acetonitrile (typically 400 to 
600 µL/well) supplemented with internal standard was added, the plates were resealed, briefly 
mixed by vortexing, and incubated for 30 min to 1 h at room temperature. The plates were then 
centrifuged (5,000 × g, 10 min), and the cleared supernatant was filtered through an AcroPrep 
96-well filter plate (0.2 µm cutoff) into a shallow-well plate for HPLC analysis. For GC-MS 
analysis, 400 µL of a 1:1 mixture of ethyl acetate and cyclohexane were added per well, the 
plates were re-sealed, and vortexed vigorously for 2 min. The plates were then centrifuged 
(5,000 × g, 10 min), and 200 µL of the upper organic phase were transferred to 2 mL vials fitted 
with 300 µL glass inserts for GC-MS analysis. 
 
Small-scale alkylation or cyclopropanation bioconversions using whole cells. Single colonies 
of E. coli BL21(DE3) cells transformed with plasmid encoding P411 variants were grown 
overnight in 3 mL LB-Amp medium at 37 ºC and 250 rpm. 2 mL of the pre-cultures were used to 
inoculate 48 mL of HB-Amp medium in 125 mL Erlenmeyer flasks. Cultures were incubated at 
37 ºC, 230 rpm for 2 h, typically reaching an OD600 = 1.5. Cultures were then cooled on ice 
(20 min) and induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression 
was conducted at 24 ºC, 130 rpm, for 16-18 h. Cultures were then cooled on ice, centrifuged 
(3000 × g, 3 min, 4 ºC), and the pellets were resuspended to OD600 = 30 in M9-N minimal 
medium. To determine P411 expression levels, aliquots of the cell suspension were subjected to 
carbon monoxide binding spectroscopy assay specified below (page S6). 
Small-scale biocatalytic alkylation or cyclopropanation reactions were set up in 2 mL crimp vials 
with 400 µL reaction volume. Typically, 370 µL of P411-expressing cells at OD600 = 30 in M9-N 
buffer were added to the vials and transferred into an anaerobic chamber (no sparging of cell 
suspensions with argon was conducted as reported previously; transfer of the cell solution to the 
anaerobic chamber, including several cycles of applying vacuum and purging with N2, proved 
sufficient for degassing). Subsequently, the vials were put on a shaker (500 rpm), and 15 µL of 
heterocycle or internal olefin stock solution (in DMSO or EtOH) were added, followed by 15 µL 
of diazo stock solution (in EtOH). Final concentrations, depending on the substrates tested, 
typically ranged from 5 to 40 mM olefin and 10 to 60 mM EDA, with 7.5 % co-solvent. For 
aerobic alkylation reactions, reactions were set up as specified above on the bench under a 
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standard atmosphere. Following addition of substrates the vials were sealed and shaken at room 
temperature, 500 rpm for 6–16 h. For sample work-up for HPLC analysis the reactions were 
quenched by adding acetonitrile supplemented with internal standards (ethyl benzoate or 1,3,5-
trimethoxybenzene). The sample solutions were incubated for 30 min, transferred to 1.5 mL 
tubes and centrifuged at 13,000 × g for 10 minutes. The cleared supernatant was transferred to 
clean 2 mL vials and analyzed by HPLC. For sample work-up for GC-MS or chiral HPLC 
analysis, the reactions were quenched by adding 400 µL of a 1:1 solution of ethyl acetate and 
cyclohexane, internal standard was added, and the mixture was transferred to 1.5 mL tubes, 
followed by vigorous vortexing for 2 min. Samples were then centrifuged (10 min, 13,000 × g) 
and 200 µL of the upper organic phase were transferred to 2 mL vials fitted with 300 µL glass 
inserts, followed by GC-MS or chiral HPLC analysis. 
 
Determination of reaction kinetics and initial rates. Kinetics of 1-methylindole alkylation 
were determined using whole E. coli cells expressing P411 variants. Reactions were set up as 
described above (Small-scale alkylation or cyclopropanation bio-conversions using whole cells). 
Following addition of substrates, reactions were quenched in defined time intervals by addition 
of 500 μL acetonitrile, followed by vigorous mixing. The vials were removed from the anaerobic 
chamber and further sample work-up and HPLC analysis was performed as described above. 
 
Determination of in vivo P411 protein stability by urea titration. P411-expressing whole E. 
coli cells were prepared as described above. Subsequently, 700 µL of cells at OD600 = 30 in 
M9-N buffer were transferred to a 1.7 mL tube, and urea stock solution (10 M) was added to 
varying final concentrations (0, 1, 2, 3 or 4 M); the total volume was adjusted to 1.2 ml with 
M9–N buffer. The resulting cell suspensions were incubated at 25°C for 30 min in a 
thermomixer (Eppendorf) at 500 rpm shake rate. Subsequently, the tubes were centrifuged 
(1000 × g, 1 min) to pellet the cells, the supernatant was discarded, and pellets were washed in 
800 uL M9-N buffer. The centrifugation step was repeated, the supernatant was discarded, and 
cells were resuspended in 800 µL M9-N buffer. Of this cell suspension, 2 × 370 µL were 
transferred to 2 mL crimp vials, and reactions for 1-methylindole alkylation were set up and 
analyzed as described above. 
 
S6 
 
Preparative scale reactions. E. coli BL21(DE3) cells freshly transformed with plasmid 
encoding P411 variants were grown overnight in 25 mL LB-Amp (37 ºC, 250 rpm). HB-Amp 
medium (500 mL) in a 2.8 L flask was inoculated with 20 mL of the pre-culture and incubated at 
37 ºC, 230 rpm for 2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water bath for 
20 min and induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was 
conducted at 24 ºC, 140 rpm, for 16-20 h. Cultures were then centrifuged (5,000 × g, 5 min, 
4 ºC) and the cell pellets were resuspended to OD600 = 40 in M9-N buffer supplemented with 
20 mM D-glucose (typically yielding ca. 110 mL of cell suspension). Aliquots of the cell 
suspension (4 mL) were used to determine the P411 expression level after cell lysis by 
sonication. Aliquots of the cell suspension (28 mL) were then transferred to 50 mL Erlenmeyer 
flasks and degassed by sparging with argon for at least 30 minutes. The reaction flasks were then 
transferred into an anaerobic chamber and olefin stock solution (1 mL, in DMSO) and EDA 
(1 mL, in EtOH) were added. Final concentrations were typically 10 to 20 mM heterocycle or 
internal olefin and 15 to 30 mM EDA, with 6.7% co-solvent. The flasks were sealed with 
parafilm, removed from the anaerobic chamber, and shaken at room temperature, 100 rpm for 
18 h. The reactions were quenched by adding acetonitrile (25 mL) and then centrifuged 
(4,000 × g, 10 min). The supernatant was concentrated in vacuo to remove acetonitrile and 
extracted with EtOAc or 1:1 EtOAc:cyclohexane (3 × 25 mL). The organic layers were washed 
with brine (20 mL), dried over MgSO4, filtered, concentrated, and purified by silica gel 
chromatography on a Biotage Isolera instrument. 
 
Determination of P411 concentration. Aliquots (4 mL) of the same E. coli cell suspensions 
used for whole-cell biocatalytic reactions were lysed by sonication (QSonica, 1 min sonication 
time, 1s on/off cycles, 40 % output). 1 mL aliquots of the cell lysate were cleared by 
centrifugation (13,000 × g, 10 min, 4°C), and the concentration of P411 enzymes in the lysate 
was determined from ferrous carbon monoxide binding difference spectra using the previously 
reported extinction coefficient for serine-ligated enzymes (ε = 103,000 M–1 cm–1). The 
concentration of purified P411 enzymes was determined by quantifying the amount of free 
hemin using the pyridine/hemochrome assay using the corresponding extinction coefficient 
(ε = 191,500 M–1 cm–1)4. 
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Protein purification. E. coli BL21(DE3) cells freshly transformed with plasmid encoding P411 
variants were grown overnight in 25 mL LB-Amp (30 ºC, 250 rpm). HB-Amp medium (500 mL) 
in a 2.8 L flask was inoculated with 20 mL of the pre-culture and incubated at 37 ºC, 230 rpm for 
2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water bath for 20 min and induced 
with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was conducted at 24 ºC, 
140 rpm, for 16-20 h. Cultures were then centrifuged (5,000 × g, 10 min, 4 ºC) and the cell 
pellets were frozen at –20 ºC. For protein purification, frozen cells from two such cultures were 
resuspended in buffer A (25 mM Tris-HCl, 20 mM imidazole, 100 mM NaCl, pH 7.5; 4 mL 
buffer per g of cell wet weight), supplemented with one protease inhibitor tablet (Roche), 
1 mg/mL lysozyme, and 0.1 mg/mL DNAse I. The cell suspensions were lysed by sonication 
(1 min sonication time, 1s on/off cycles, 40 % output). To pellet insoluble material, cell lysates 
were centrifuged (20,000 × g, 20 min, 4 ºC), followed by filtering the cleared lysate through a 
2 µM syringe-driven filter unit. P411 proteins were purified from the lysate using a nickel NTA 
column (1 mL HisTrap HP, GE Healthcare) using an AKTAxpress purifier FPLC system (GE 
Healthcare). P411 enzymes were eluted on a linear gradient from 100% buffer A to 100% buffer 
B (25 mM Tris-HCl, 300 mM imidazole, 100 mM NaCl, pH 7.5) over 10 column volumes. 
Fractions containing eluted protein were pooled and subjected to three rounds of buffer exchange 
to storage buffer (25 mM Tris-HCl, 100 mM NaCl, pH 7.5) using centrifugal spin filters (10 kDa 
molecular weight cut-off, Amicon Ultra). Subsequently, the concentrated protein was aliquoted, 
flash-frozen on powdered dry ice, and stored at –80 ºC. Protein concentrations were determined 
using the pyridine/hemochrome assay specified above. 
 
Alkylation reactions using purified protein. Portions of M9-N buffer (290 µL) and NADPH 
(40 µL, 50 mM in M9-N) or sodium dithionite (40 µL, 50 mM in M9-N), or multiples thereof, 
were combined in a 6 mL crimp vial and degassed by sparging with argon for at least 
30 minutes. Purified protein solutions were adjusted to 25 µM in M9-N. After degassing was 
complete, the M9-N/reductant solution and purified protein stocks were brought into the 
anaerobic chamber. Reactions were set up on a 400 µL scale in 2 mL crimp vials: first, 340 µL 
of the M9-N/reductant solution were added per vial, followed by 40 µL of purified protein 
solution. Next, 10 µL of heterocycle or internal olefin stock solution were added, followed by 
10 μL of EDA stock solution. Final concentrations were typically 5 mM heterocycle or internal 
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olefin, 7.5 mM EDA, 5 mM reductant, and 2.5 μM P411, with 5% co-solvent. The vials were 
sealed, removed from the anaerobic chamber, and shaken at room temperature, 40 rpm for 1 to 
6 h. The reactions were quenched by adding acetonitrile (400 μL) supplemented with internal 
standard. This mixture was transferred to a 1.5 mL tube and centrifuged at 13,000 × g for 
10 minutes. The supernatant was transferred to 2 mL vials and analyzed by HPLC. 
 
Chemical synthesis of alkylation or cyclopropanation authentic product standards. The 
general protocol followed to synthesize authentic product standards is provided. In a fume hood, 
a 25 mL round-bottom flask with a stir bar was evacuated and back-filled with argon three times. 
10 mL of anhydrous dichloromethane were added, followed by 0.02 mmol (9 mg) of rhodium(II) 
acetate dimer. While stirring, 1.0 mmol of neat heterocycle or internal olefin were added, and 
1.5 mmol of neat diazo compound were added over 2 h using a syringe pump. Following 
addition of the diazo compound, the reaction mixture was stirred at room temperature under 
argon over 16 h. The reaction mixture was concentrated in vacuo, and the crude mixture was 
purified by silica flash chromatography using ethyl acetate and hexanes as mobile phase on a 
Biotage Isolera instrument. 
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II. Supplementary Tables 
 
Supplementary Table 1. Hemoprotein variant screening for 1-methylindole alkylation. 
 
 
Hemoprotein 
varianta 
Description, mutations, references 
Yield 3 
[%] 
TTN 
Heminb Free hemin in buffer, no protein 9 18 
E. coli BL21(DE3) 
Whole E. coli cells, no protein 
overexpression 
4 n.d. 
P450BM3 Wild-type P450BM3 2 22 
P450BM3 T268A 
C400S 
P450BM3 with mutations T268A and 
C400S3 
7 183 
P450BM3-CIS 
P450BM3 with mutations V78A F87V 
P142S T175I A184V S226R H236Q 
E252G T268A A290V L353V I366V 
E442K3 
5 53 
P411BM3-CIS 
P450BM3 with mutations V78A F87V 
P142S T175I A184V S226R H236Q 
E252G T268A A290V L353V I366V 
C400S E442K3 
14 691 
HStar H92N 
H100N 
P450BM3 with mutations V78M H92N 
H100N L181V T268A C400H L437W4,5 
3 570 
P450-Cam P450cam from Pseudomonas putida6 3 273 
Cyp119 Cyp119 from Sulfolobus acidocaldarius7 6 n.d. 
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a Reactions were performed on 400 µL scale with whole E. coli cells expressing the respective 
hemoprotein variants, at 10 mM substrate loading (1-methylindole; with 15 mM EDA). Results 
are the average of duplicate reactions. TTN (total turnover numbers) are defined as HPLC-
determined product concentrations divided by hemoprotein concentrations as measured by CO 
binding difference spectroscopy. n.d. = not detected. b Reaction with hemin: in the anaerobic 
chamber, 10 µL of hemin solution (2 mM in DMSO) were added to 350 µL of argon-sparged 
M9-N buffer, followed by 20 µL of sodium dithionite as reductant (100 mM in M9-N buffer), 
1-methylindole (10 μL, 400 mM in DMSO) and EDA (10 μL, 600 mM in EtOH). Final 
concentrations were 50 μM hemin, 5 mM sodium dithionite, 10 mM 1-methylindole and 15 mM 
EDA with 5 % co-solvent.   
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Supplementary Table 2. Summary of directed evolution for 1-methylindole alkylation. 
Round Parent variant Libraries evaluateda Screening 
substrates 
Mutations 
identified 
1a P411BM3-CIS 
Single site-saturation at 
positions V87, L181, 
I263, L437 and T438 
1-methylindole, 
EDA, anaerobic 
V87T, 
L181G/I/L/R, 
I263M/G/W, 
L437G/Q, 
T438C/T 
1b P411BM3-CIS 
Random mutagenesis of 
reductase domain 
(residues 460-1048) 
1-methylindole, 
EDA, anaerobic 
Various stop 
codons in 
region 620-720, 
e.g. Q674* 
2 P411BM3-CIS 
Recombination of 
mutations identified in 
rounds 1a and 1bb: V87T, 
L181G/I/L/R, 
I263M/G/W, L437G/Q, 
T438C/T, Q674* 
1-methylindole, 
EDA, anaerobic 
V87T, L181G, 
I263M, V281Lc, 
T438C, Q674* 
3 
P411BM3-CIS 
V87T L181G 
I263M V281L 
T438C Q674* 
Random mutagenesis of 
heme domain, followed by 
recombination of 
improved variantsd 
1-methylindole, 
EDA, aerobic 
N201S, L215Q 
4 
P411BM3-CIS 
V87T L181G 
N201S L215Q 
I263M V281L 
T438C Q674* 
Random mutagenesis of 
FMN domain (residues 
460-674) 
1-methylindole, 
EDA, aerobic 
K472T, N573D, 
F646S 
5a P411BM3-CIS Random mutagenesis of 1-methylindole, No further hits 
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V87T L181G 
N201S L215Q 
I263M V281L 
T438C K472T 
N573D F646S 
Q674* 
entire heme-FMN domain 
open reading frame 
(residues 1-674) 
EDA, aerobic identified 
5b 
P411BM3-CIS 
V87T L181G 
N201S L215Q 
I263M V281L 
T438C K472T 
N573D F646S 
Q674* 
Double site-saturation at 
positions H92_H100 and 
F391_Q403; single site-
saturation at positions 
L75, A82 and L437 
1-methylindole, 
EDA, aerobic 
H92F 
6 
P411BM3-CIS 
V87T H92F 
L181G N201S 
L215Q I263M 
V281L T438C 
K472T N573D 
F646S Q674* 
Double site-saturation at 
positions T327 and A328 
1-methylindole, 
EDA, aerobic 
T327P A328S 
Final variant: P411-HF = P411BM3-CIS V87T H92F L181G N201S L215Q I263M V281L 
T438C K472T N573D F646S Q674* 
Best variant for aerobic conditions: P411BM3-CIS V87T H92F L181G N201S L215Q I263M 
V281L T327P A328S T438C K472T N573D F646S Q674* (= P411-HF T327P A328S) 
 
a Some residues were saturated twice, in different parent variants. b The corresponding wild-type 
residues at each position were included in the recombination library. c Mutation V281L arose as 
an additional random mutation in the best variant identified from the recombination library; this 
position was subsequently subjected to site-saturation mutagenesis, confirming 281L as the 
optimal residue. d Library screening identified an improved variant with point mutations N201T 
S13 
 
and L215V. For recombining these mutations, a library was cloned and tested with an expanded 
codon set at both positions, consisting of a WNT codon at position 201 (encoding C, F, I, N, T, 
Y, S) and a VWM codon at position 215 (encoding D, E, H, K, N, Q, I, L, V). This resulted in an 
improved variant with mutations N201S and L215Q. 
 
 
 
 
 
Supplementary Table 3. Summary of 1-methylpyrrole alkylation with EDA (Figure 4A). 
Varianta Substrate 
Loading (mM) 
Yield (%) P411 (µM) TTN Ratio 
4b:4a 
P411-HF  10 3.8 ± 0.6 2 ± 0.15 184 ± 23.3 74:26 
P411-HF M263T 10 4.8 ± 0.4 2.1 ± 0.1 230 ± 13.4 49:51 
P411-HF M263T 
G181E 
10 12.4 ± 0.6 2.7 ± 0.1 458 ± 9.9 
17:83 
P411-HF M263T 
G181E A82T 
10 20.7 ± 0.9 2.9 ± 0.12 705 ± 6.9 
9:91 
P411-HF M263T 
T87W 
10 7.2 ± 0.3 3.0 ± 0.1 242 ± 4.7 
93:7 
P411-HF M263T 
T87W G181K 
10 19.3 ± 0.8 3.9 ± 0.05 485 ± 18.1 
98:2 
 
a Reactions were performed with P411-expressing E. coli at OD600=30, at RT, for 16 h. 
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Supplementary Table 4. Summary of 1-methylindole alkylation with Me-EDA (Figure 4B). 
Varianta Substrate 
Loading (mM) 
Yield (%) P411 (µM) TTN 
P411-HF M263Y 10 < 0.1 1.7 ± 0.02 2 ± 0.8 
P411-HF M263Y 
T87C 
10 0.1 ± 0.01 1.5 ± 0.06 5 ± 0.7 
P411-HF T87C 
Y263E 
10 0.3 ± 0.05 1.7 ± 0.04 15 ± 3.0 
P411-HF T87C 
Y263E A328Y 
10 0.7 ± 0.08 2.4 ± 0.06 31 ± 3.6 
P411-HF T87C 
Y263E A328Y 
L437M 
10 1.0 ± 0.15 2.1 ± 0.09 47 ± 7.3 
P411-HF T87C 
Y263E A328Y 
L437M A268G 
10 3.1 ± 0.24 1.7 ± 0.06 181 ± 12.6 
P411-HF T87C 
Y263E A328Y 
L437M A268G 
T327P 
10 6.0 ± 0.26 3.1 ± 0.09 193 ± 5.4 
P411-HF Y263E 
A328Y L437M 
A268G T327P 
C87A 
10 22.9 ± 2.43 3.0 ± 0.05 776 ± 79.4 
 
a Reactions were performed with P411-expressing E. coli at OD600=30, at RT, for 16 h. 
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Supplementary Table 5. Summary of indene cyclopropanation with EDA (Figure 4C). 
Varianta Substrate 
Loading (mM) 
Yield 
(%) 
P411 
(µM) 
TTN dr ee 
(%) 
P411-CIS 10 5 ± 0.5 1.7 ± 0.12 307 ± 23 69:31 73 
P411-HF 10 39 ± 3.0 2.1 ± 0.15 1881 ± 59 95:5 94 
P411-HF M263Y 10 49 ± 4.9 1.3 ± 0.13 3996 ± 43 97:3 96 
 
a Reactions were performed with P411-expressing E. coli at OD600=30, at RT, for 16 h. 
 
 
 
 
Supplementary Table 6. Summary of 1,3-cyclohexadiene cyclopropanation with EDA (Figure 
4C). 
Varianta Substrate 
Loading (mM) 
Yield (%) P411 
(µM) 
TTN dr ee 
(%) 
P411-CIS 10 0.2 ± 0.02 1.8 ± 0.29 11 ± 1.4 90:10 n.d. 
P411-HF 10 0.3 ± 0.04 2.0 ± 0.22 14 ± 1.1 89:11 n.d. 
P411-HF 
M263W G181L 
10 3.2 ± 1.4 3.2 ± 0.54 98 ± 27 
91:9 
73 
 
a Reactions were performed with P411-expressing E. coli at OD600=30, at RT, for 16 h. 
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III Supplementary Figures 
 
Supplementary Figure 1: Development of a UV-Vis spectrophotometric high-throughput 
screening assay for 1-methylindole alkylation. 
 
(A) Directed evolution screening reaction using 1-methylindole 1 and EDA 2 to yield the C3-
alkylated product 3a. (B) Absorbance of 1 and 3a, both at 1 mM concentration, in 1:1 
H2O:MeCN, showing a pronounced red-shift for the alkylation product 3a. (C) Exemplary data 
for the UV-Vis high-throughput alkylation screen. Shown are 96 individual whole-cell reactions 
of either random mutagenesis library variants (grey dots), P411-CIS (parent variant, red dots, in 
quadruplicate) and P450-BM3 (negative control, black dots, in quadruplicate). Absorbance at 
305 nm indicates enzymatic activity for catalytic production of 3a. Potentially improved variants 
(showing higher absorption than the corresponding parent variants) were subsequently analyzed 
by HPLC to verify and quantify higher biocatalytic activity for the production of 3a. Availability 
of a rapid UV-Vis screening system is noteworthy: optimization of hemoproteins for most 
carbene transfer reactions reported to date typically required measurement of enzymatic activity 
and/or selectivity by liquid chromatography (LC) or gas chromatography (GC). As these 
techniques are time-consuming (several minutes per run, or several hours per 96-well plate), 
evolutionary strategies to optimize carbene transferases typically employed iterative, single site-
saturation mutagenesis of active-site residues, thereby keeping library sizes sufficiently small for 
the limited throughput of LC or GC. However, for P450-BM3, a protein of 1048 residues, this 
neglects a considerable amount of protein sequence space. Thus, we were pleased to have the 
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high-throughput spectrophotometric indole alkylation assay for facile screening of several 
thousand enzyme variants per generation. This screening system enabled us to search for 
improved carbene transfer activity across the entire P450-BM3 protein sequence space using 
random mutagenesis of both the heme and reductase domains, complemented by site-saturation 
mutagenesis of selected heme domain active site residues. 
 
Supplementary Figure 2: Position of mutations in P411-HF. 
 
 
 
 
 
 
 
 
 
 
 
 
Structural model of wild-type P450-BM3 heme and FMN domains (pdb: 1BVY8). The heme 
domain is shown on the left in light gray, while the FMN domain is on the right in dark gray; 
both heme and FMN co-factors are shown in red. The heme domain active site cavity is on the 
left side of the heme co-factor. The FAD domain is missing in both P411-HF and in this crystal 
structure (included here are heme domain residues 20-458 and FMN domain residues 479-630). 
Residues mutated in P411-HF are shown in blue; note that P411-CIS, the evolutionary starting 
point, carries a F87V mutation, however, since the structure shown here is derived from P450-
BM3, F is shown at position 87. P411-HF mutations K472T and F646S are not shown, as these 
residues are not included in the crystal structure.   
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Supplementary Figure 3: Sequential substrate addition and substrate pre-incubation experiments. 
 
(A) Sequential substrate addition experiment: Equivalents of 1-methylindole and EDA (10 mM 
each) were added to P411-HF whole-cell reactions every 30 min, up to a substrate loading of 60 
mM. For reactions receiving less substrate, solvent was added at the indicated time points to 
ensure equal volume and solvent concentration across all samples. Samples were worked-up and 
analyzed 2 h after the last substrate addition. The data indicate that substrate availability is not 
limiting enzymatic turnover numbers. (B) Substrate pre-incubation experiment: P411-HF 
expressing whole cells were pre-incubated with either 1-methylindole (30 mM) or EDA (45 mM) 
for 15 min, before adding the corresponding second substrate. Activity was compared to whole-
cell reactions receiving both substrate simultaneously. 1-Methylindole pre-incubation caused an 
8% reduction in activity, while EDA pre-incubation resulted in a 26% activity loss, indicative of 
enzyme inactivation by alkylation. Data shown in (A) and (B) were derived from reactions 
performed in duplicate; error bars indicated standard deviation. 
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Supplementary Figure 4: Investigating the effects of FAD domain truncation. 
 
 
 
(A) Comparison of P411-CIS and P411-CIS Q674* yield and TTN for the alkylation of 
1-methylindole (10 mM) with EDA (15 mM) to yield product 3a. (B) Comparison of P411-
VACcis and P411-VACcis Q674* for the cyclopropanation of N-vinylphthalimide (30 mM) with 
EDA (30 mM; product analysis by HPLC was performed as previously described10), conducted 
with cells at OD600=10. (C) Urea titration assay to assess in vivo P411 variant stability.11,12 
E. coli cells expressing the indicated P411 variants were treated with different concentrations of 
the protein denaturant urea, followed by assessing the remaining 1-methylindole alkylation 
activity. Data shown in (A) to (C) were derived from two independent assays with reactions 
performed in duplicate; error bars indicated standard deviation. 
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Supplementary Figure 5: In vitro 1-methylindole alkylation activity of purified P411 variants. 
 
 
In vitro 1-methylindole alkylation activity of purified P411 variants was tested using either 
NADPH or sodium dithionite as reductant, or no externally added reductant. Assays were 
conducted with 5 mM 1-methylindole, 7.5 mM EDA, 5 mM reductant and 2.5 µM enzyme in 
M9-N buffer. The highest catalytic activity, observed with P411-HF and NADPH as reductant, 
corresponds to 94% product yield. 
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Supplementary Figure 6: Evolution of P411-HF for 1-methylpyrrole alkylation with EDA. 
 
 
 
Evolutionary lineage from P411-HF over three generations to yield variants selective for C2 or 
C3 1-methylpyrrole alkylation with EDA. Data were derived from two independent experiments 
performed in duplicate; assays were performed with 10 mM substrate loading (1-methylpyrrole 
and EDA). See Supplementary Table 3 for experimental details. 
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Supplementary Figure 7: Evolution of P411-HF for 1-methylindole alkylation with Me-EDA. 
 
 
 
Evolutionary lineage from P411-HF M263Y over seven generations to yield a > 300-fold 
improved variant in the alkylation of 1-methylindole with Me-EDA (775 TTN and 49% ee); 
substrate loading was 10 mM 1-methylindole and 15 mM Me-EDA. Data were derived from two 
independent experiments performed in duplicate; error bars indicate standard deviation. 
Enantioselectivity was not determined for the first four variants due to low activity; absolute 
stereochemistry was not assigned. See Supplementary Table 4 for experimental details. 
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Supplementary Figure 8: Evolution of P411-HF for indene and 1,3-cyclohexadiene 
cyclopropanation with EDA. 
 
 
Activities of parent and evolved enzyme variants for indene (A) and 1,3-cyclohexadiene (B) 
cyclopropanation with EDA. Assays were conducted with 10 mM olefin and 15 mM EDA. Data 
were derived from two independent experiments performed in duplicate; error bars indicate 
standard deviation. See Supplementary Tables 5 and 6 for experimental details. Reactions with 
hemin were set up as described in the footnotes to Supplementary Table 1. 
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Supplementary Figure 9: HPLC calibration curve for 1-methylindole alkylation with EDA. 
Product: 
 
 
 
Column: Kromasil 100-5-C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 260 nm 
 
 
Supplementary Figure 10: HPLC calibration curve for 1-methylindole alkylation with Me-EDA. 
Product: 
 
 
 
Column: Poroshell 120 C18 
Standard: 1,3,5-trimethoxybenzene 
Wavelength: 220 nm 
 
 
Supplementary Figure 11: HPLC calibration curve for 1,2-dimethylindole alkylation with EDA. 
Product: 
 
 
 
Column: Poroshell 120 C18 
Standard: Ethyl benzoate 
Wavelength: 260 nm 
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Supplementary Figure 12: HPLC calibration curve for 1-methylpyrrole C3-alkylation with EDA. 
Product: 
 
 
 
Column: Poroshell 120 C18 
Standard: Ethyl benzoate 
Wavelength: 210 nm 
 
 
Supplementary Figure 13: HPLC calibration curve for 1-methylpyrrole C2-alkylation with EDA. 
Product: 
 
 
 
Column: Poroshell 120 C18 
Standard: Ethyl benzoate 
Wavelength: 210 nm 
 
 
Supplementary Figure 14: HPLC calibration curve for indene cyclopropanation with EDA. 
Product: 
 
 
 
Column: Kromasil 100-5-C18 
Standard: Ethyl benzoate 
Wavelength: 260 nm 
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Supplementary Figure 15: GC-MS calibration curve for 1,3-cyclohexadiene cyclopropanation 
with EDA. 
Product: 
 
 
 
Column: J&W HP-5ms 
Standard: 1,3,5-trimethoxybenzene 
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IV. Characterization of reaction products 
Preparative-scale whole-cell reactions with P411 variants were performed according to the 
protocol described above (page S6). Spectral data of known compounds are in agreement with 
reported values. A full characterization was performed for novel compounds. 
 
 
 
 
 
3a: Ethyl 2-(1-methyl-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.6 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 20 mM 1-methylindole (added as 1 mL of a 600 mM 
solution in DMSO) and 30 mM EDA (added as 1 mL of a 900 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
clear oil (108 mg, 83% yield, 5350 TTN). 1H NMR (400 MHz, Chloroform-d) δ 7.64 (dt, J = 8.0, 
1.0 Hz, 1H), 7.33 (dt, J = 8.2, 1.0 Hz, 1H), 7.26 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.15 (ddd, J = 
8.0, 6.9, 1.1 Hz, 1H), 7.08 (d, J = 1.0 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.81 – 3.76 (m, 5H), 
1.29 (t, J = 7.1 Hz, 3H). 
 
 
 
 
 
3b: Ethyl 2-(1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was performed on 
0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N buffer expressing 
P411-HF at 3.1 µM, with 10 mM indole (added as 1 mL of a 300 mM solution in DMSO) and 
15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The product was purified by silica 
gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a white solid (43 mg, 71% yield, 
2280 TTN). 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.56 (ddt, J = 7.8, 1.4, 0.7 Hz, 1H), 7.28 
(dt, J = 8.1, 0.9 Hz, 1H), 7.13 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.06 (ddd, 
J = 8.0, 7.1, 1.1 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.70 (d, J = 0.9 Hz, 2H), 1.19 (t, J = 7.1 Hz, 
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3H). 13C NMR (101 MHz, CDCl3) δ 172.21, 136.22, 127.39, 123.13, 122.32, 119.77, 119.06, 
111.28, 108.77, 60.92, 31.57, 14.39. 
 
 
 
 
 
3c: Ethyl 2-(1,2-dimethyl-1H-indol-3-yl)acetate. Reactions with 1,2-dimethylindole were 
performed on analytical scale (400 µL reactions) with variant P411-HF M263A and reaction 
yield was analyzed by HPLC. Authentic product standard was obtained through rhodium acetate 
catalyzed alkylation of 1,2-dimethylindole with EDA following the protocol described above. 1H 
NMR (400 MHz, CDCl3) δ 7.60 – 7.51 (m, 1H), 7.28 – 7.23 (m, 1H), 7.16 (ddd, J = 8.2, 7.0, 1.2 
Hz, 1H), 7.10 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.71 (s, 2H), 3.67 (s, 3H), 
2.41 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.31, 136.60, 134.58, 
127.67, 120.89, 119.25, 118.18, 108.75, 103.92, 60.78, 30.88, 29.74, 14.39, 10.55. 
 
 
 
 
 
3d: Ethyl 2-(5-methyl-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 5-methylindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (18 mg, 28% yield, 1130 TTN). 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.46 – 
7.37 (m, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 2.4 Hz, 1H), 7.03 (dd, J = 8.3, 1.6 Hz, 1H), 
4.18 (q, J = 7.1 Hz, 2H), 3.75 (d, J = 0.9 Hz, 2H), 2.46 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 172.30, 134.54, 129.00, 127.60, 123.92, 123.26, 118.67, 110.94, 
108.21, 60.89, 31.57, 21.67, 14.37. 
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3e: Ethyl 2-(5-methoxy-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 5-methoxylindole (added as 1 mL of a 
300 mM solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). 
The product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated 
as a white solid (12 mg, 17% yield, 700 TTN). 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.24 
(dd, J = 8.8, 0.6 Hz, 1H), 7.15 (d, J = 2.6 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.86 (dd, J = 8.8, 2.4 
Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.74 (d, J = 0.9 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.20, 154.28, 131.34, 127.77, 123.89, 112.67, 112.03, 108.50, 
100.77, 60.92, 56.00, 31.68, 14.42. 
 
 
 
 
 
3f: Ethyl 2-(6-methoxy-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 6-methoxylindole (added as 1 mL of a 
300 mM solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). 
The product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated 
as a white solid (47 mg, 67% yield, 2170 TTN). 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.49 
(d, J = 8.5 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 6.87 – 6.77 (m, 2H), 4.17 (q, J = 7.1 Hz, 2H), 3.84 
(s, 3H), 3.73 (d, J = 1.0 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.24, 
156.72, 136.99, 121.88, 121.80, 119.72, 109.79, 108.71, 94.73, 60.91, 55.80, 31.68, 14.38. 
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3g: Ethyl 2-(6-chloro-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 6-chlorolindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (41 mg, 58% yield, 1860 TTN). 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.52 (d, 
J = 8.5 Hz, 1H), 7.37 – 7.31 (m, 1H), 7.18 – 7.14 (m, 1H), 7.10 (dd, J = 8.5, 1.8 Hz, 1H), 4.17 (q, 
J = 7.1 Hz, 2H), 3.74 (d, J = 0.9 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 171.95, 136.56, 128.31, 126.02, 123.78, 120.56, 120.02, 111.21, 109.02, 61.04, 31.45, 14.38. 
 
 
 
 
 
3h: Ethyl 2-(6-bromo-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 6-bromoindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (41 mg, 48% yield, 1560 TTN). 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 7.51 (d, 
J = 1.6 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.23 (dd, J = 8.5, 1.7 Hz, 1H), 7.18 – 7.12 (m, 1H), 
4.16 (q, J = 7.1 Hz, 2H), 3.74 (d, J = 0.9 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 171.90, 136.99, 126.34, 123.71, 123.14, 120.42, 115.95, 114.20, 109.12, 61.04, 31.43, 
14.38. 
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3i: Ethyl 2-(7-methyl-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 7-methylindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (48 mg, 74% yield, 2380 TTN). 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.49 (dq, 
J = 7.9, 1.4, 0.7 Hz, 1H), 7.21 – 7.15 (m, 1H), 7.07 (dd, J = 7.8, 7.1 Hz, 1H), 7.01 (dt, J = 7.1, 
1.0 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.78 (d, J = 0.9 Hz, 2H), 2.54 – 2.42 (m, 3H), 1.27 (t, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.26, 135.80, 126.91, 122.86, 122.82, 120.45, 
119.98, 116.75, 109.21, 60.90, 31.69, 16.68, 14.38. 
 
 
 
 
 
3j: Ethyl 2-(7-chloro-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 7-chloroindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (45 mg, 63% yield, 2040 TTN). 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 7.53 (dt, 
J = 7.9, 0.7 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.20 (dd, J = 7.6, 0.7 Hz, 1H), 7.07 (t, J = 7.8 Hz, 1H), 
4.17 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 0.9 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 171.87, 133.50, 128.85, 123.80, 121.70, 120.58, 117.79, 116.78, 109.93, 61.04, 31.60, 
14.37. 
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3k: Ethyl 2-(7-bromo-1H-indol-3-yl)acetate. An enzymatic preparative-scale reaction was 
performed on 0.3 mmol scale with E. coli whole-cell catalysts at OD600 = 40 in 28 mL M9-N 
buffer expressing P411-HF at 3.1 µM, with 10 mM 7-bromoindole (added as 1 mL of a 300 mM 
solution in DMSO) and 15 mM EDA (added as 1 mL of a 450 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 15% EtOAc/hexanes) and isolated as a 
white solid (44 mg, 52% yield, 1680 TTN). 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.57 (dt, 
J = 7.9, 0.8 Hz, 1H), 7.36 (dd, J = 7.6, 0.9 Hz, 1H), 7.25 (d, J = 2.1 Hz, 1H), 7.02 (t, J = 7.8 Hz, 
1H), 4.17 (q, J = 7.2 Hz, 2H), 3.75 (d, J = 0.9 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 171.67, 134.80, 128.45, 124.56, 123.60, 120.86, 118.28, 109.99, 104.78, 60.91, 
31.54, 14.25. 
 
 
 
 
 
4a: Ethyl 2-(1-methyl-1H-pyrrol-3-yl)acetate. Reactions with 1-methylpyrrole were performed 
on analytical scale (400 µL reactions) with P411-HF variants shown in Figure 4A (main text) 
and Supplementary Figure 6, and yield and regioselectivity were analyzed by HPLC. Authentic 
product standard for the C3-alkylated product was obtained through preparative-scale whole-cell 
enzymatic alkylation of 1-methylpyrrole with EDA using variant P411-HF M263T G181E 
A82T. The reaction was performed on 0.3 mmol scale, followed by a first purification by silica 
flash chromatography and a second purification by preparative HPLC using a Agilent XDB C18 
column (9.5 x 250 mM, 5 µM). 1H NMR (400 MHz, CDCl3) δ 6.59 – 6.56 (m, 1H), 6.55 (t, J = 
2.4 Hz, 1H), 6.09 (dd, J = 2.3 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.64 (s, 3H), 3.49 (s, 2H), 1.29 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.77, 121.91, 120.66, 115.79, 109.10, 
60.72, 36.28, 33.27, 14.39. 
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4b: Ethyl 2-(1-methyl-1H-pyrrol-2-yl)acetate. Reactions with 1-methylpyrrole were performed 
on analytical scale (400 µL reactions) with P411-HF variants shown in Figure 4A (main text) 
and Supplementary Figure 6, and yield and regioselectivity were analyzed by HPLC. Authentic 
product standard for the C2-alkylated product was obtained through rhodium acetate catalyzed 
alkylation of 1-methylpyrrole with EDA following the standard protocol described above. 1H 
NMR (400 MHz, CDCl3) δ 6.59 (t, J = 2.6, 1.9 Hz, 1H), 6.07 (t, J = 3.4, 2.7 Hz, 1H), 6.04 (ddt, J 
= 3.5, 1.9, 0.5 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.61 (s, 2H), 3.58 (s, 3H), 1.26 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.73, 125.09, 122.62, 108.78, 107.09, 61.14, 34.07, 
32.84, 14.33. 
 
 
 
 
 
 
 
5: Ethyl 2-(1-methyl-1H-indol-3-yl)propanoate. Reactions with 1-methylindole and ethyl-2-
diazopropanoate (Me-EDA) were performed on analytical scale (400 µL reactions) with P411-
HF variants shown in Figure 4B (main text) and Supplementary Figure 7, and yield was analyzed 
by HPLC. Authentic product standards were obtained through rhodium acetate catalyzed 
alkylation of 1-methylindole with ethyl-2-diazopropanoate following the standard protocol 
described above. 1H NMR (400 MHz, CDCl3) δ 7.69 (dt, J = 8.0, 1.0 Hz, 1H), 7.30 (dt, J = 8.2, 
0.9 Hz, 1H), 7.23 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.12 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 7.01 (s, 
1H), 4.14 (qq, J = 10.8, 7.1 Hz, 2H), 4.01 (qd, J = 7.2, 0.6 Hz, 1H), 3.76 (s, 3H), 1.60 (d, J = 7.2 
Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.25, 136.93, 126.83, 
126.21, 121.68, 119.34, 118.98, 114.05, 109.25, 60.64, 36.98, 32.73, 18.04, 14.21. 
 
Determination of enantioselectivity for 1-methylindole alkylation with ethyl-2-
diazopropanoate. Reaction mixtures were extracted with cyclohexane, or purified standard 
compounds were dissolved in 20% isopropanol in hexanes, and samples were analyzed by chiral 
SFC using a Chiralpak IC column (10% isopropanol, isocratic).  
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H
H
CO2Et
Ethyl 2-(1-methyl-1H-indol-3-yl)propanoate authentic standard, racemic: 
 
P411-HF M263E A328Y L437M A268G T327P T87A: 
 
 
 
 
 
6a: Ethyl 1,1a,6,6a-tetrahydrocyclopropa[a]indene-1-carboxylate. Reactions with indene 
were performed on analytical scale (400 µL reactions) with P411-HA variants shown in Figure 
4C (main text) and Supplementary Figure 8, and yield and diastereoselectivity were analyzed by 
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HPLC. Authentic product standards were obtained through rhodium acetate catalyzed 
cyclopropanation of indene with EDA following the standard protocol described above. 1H NMR 
(300 MHz, Chloroform-d) δ 7.35 – 7.27 (m, 1H), 7.17 – 7.10 (m, 3H), 3.84 (q, J = 7.1 Hz, 2H), 
3.37 (d, J = 17.2 Hz, 1H), 3.21 (dd, J = 17.2, 6.7 Hz, 1H), 2.96 (ddd, J = 8.5, 6.2, 1.4 Hz, 1H), 
2.28 (dddd, J = 7.9, 6.6, 6.1, 1.0 Hz, 1H), 2.02 (t, J = 8.2 Hz, 1H), 0.96 (t, J = 7.1 Hz, 3H). 
 
Determination of indene cyclopropanation enantioselectivity. Reaction mixtures were 
extracted with cyclohexane, or purified standard compounds were dissolved in 20% isopropanol 
in hexanes, and samples were analyzed by chiral SFC using a Chiralpak IC column (5% 
isopropanol, isocratic). 
 
Ethyl 1,1a,6,6a-tetrahydrocyclopropa[a]indene-1-carboxylate authentic standard, cis isomer, 
racemic: 
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CO2Et
H
H
P411-HF M263Y: 
 
 
 
 
 
6b: Ethyl bicyclo[4.1.0]hept-2-ene-7-carboxylate. Reactions with 1,3-cyclohexadiene were 
performed on analytical scale (400 µL reactions) with P411-HF variants shown in Figure 4C 
(main text) and Supplementary Figure 8, and yield and diastereoselectivity were analyzed by 
GC-MS. Authentic product standards were obtained through rhodium acetate catalyzed 
cyclopropanation of 1,3-cyclohexadiene with EDA following the standard protocol described 
above. 1H NMR (400 MHz, CDCl3) δ 6.04 – 5.94 (m, 1H), 5.59 – 5.50 (m, 1H), 4.11 (q, J = 7.1 
Hz, 2H), 2.08 – 1.96 (m, 2H), 1.96 – 1.89 (m, 1H), 1.87 – 1.81 (m, 2H), 1.81 – 1.71 (m, 1H), 
1.70 – 1.60 (m, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.53, 125.61, 
125.32, 60.54, 25.17, 24.20, 21.09, 20.69, 17.66, 14.43. 
 
Determination of 1,3-cyclohexadiene cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified standard compounds were dissolved in 20% 
isopropanol in hexanes, and samples were analyzed by chiral SFC using a Chiralpak IA column 
(3% isopropanol, isocratic). 
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Ethyl bicyclo[4.1.0]hept-2-ene-7-carboxylate authentic standard, cis isomer, racemic: 
 
 
1,3-cyclohexadiene P411-HF M263W G181L: 
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V. NMR spectra of compounds 
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VI. Nucleotide and amino acid sequences of evolved P411 variants 
 
Nucleotide sequence of cytochrome P411-HF 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCG
TTATTAAACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGA
GAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCG
TCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCGCT
GAAATTTGCACGTGATTTTGCAGGAGACGGGTTAACCACAAGCTGGACGTTTGAAA
AAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGCAATGA
AAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGA
GCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAACGC
TTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATC
AGCCTCATCCATTTATTATAAGTATGGTCCGTGCAGGAGATGAAGTAATGAACAAG
CTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAATCTAAGCGCCAGTTTCA
AGAAGATATCAAGGTGATGAACGACCAAGTAGATAAAATTATTGCAGATCGCAAAG
CAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCA
GAAACGGGTGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTT
AATGGCGGGACACGAAGCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTATT
GAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCACGAGTTCTAGTAG
ATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAA
ACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAA
GATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCT
GATTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTC
CGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTT
TGGAAACGGTCAGCGTGCGTCTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACG
CTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCATACAAACTACGAG
CTCGATATTAAAGAAACTCTATGCTTAAAACCTAAAGGCTTTGTGGTAAAAGCAAAA
TCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAA
AAAAGTACGCACAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACG
GTTCAAATATGGGTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATG
AGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGATTCACACGCTGGAAATCTTC
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CGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGAT
AACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGG
CGTTCGCTACTCCGTATTTGGATGCGGCGATAAAGACTGGGCTACTACGTATCAAA
AAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCT
GACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGC
GTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGT
GAAGATAATAAATCTACTCTTTCACTTCAATCTGTCGACAGCGCCGCGGATATGCC
GCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGCAAAGAACTTC
AATGA 
 
Amino acid sequence of cytochrome P411-HF 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIK
EACDESRFDKNLSQALKFARDFAGDGLTTSWTFEKNWKKAHNILLPSFSQQAMKGYH
AMMVDIAVQLVQKWERLNADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFII
SMVRAGDEVMNKLQRANPDDPAYDESKRQFQEDIKVMNDQVDKIIADRKARGEQSDD
LLTQMLNGKDPETGEPLDDGNIRYQIITFLMAGHEATSGLLSFALYFLLKNPHVLQKVAE
EAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEK
GDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRASIGQQFA
LHEATLVLGMMLKHFDFEDHTNYELDIKETLCLKPKGFVVKAKSKKIPLGGIPSPSTEQS
AKKVRTKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLP
REGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKDWATTYQK
VPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDN
KSTLSLQSVDSAADMPLAKMHGAFSTNVVASKELQ*
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